Research commissioned by PHE showed that about two-thirds of the population were very likely to take-up the vaccine, around 10% were unlikely, and the rest were uncertain. For those who were uncertain or unlikely to have the vaccine, efficacy and safety were the key issues. We asked witnesses what were the key risks to public confidence in the COVID-19 vaccines. NHSE&I that these were very similar to other vaccine programmes that the NHS ran successfully each year, but that the scale of the p...

Research commissioned by PHE showed that about two-thirds of the population were very likely to take-up the vaccine, around 10% were unlikely, and the rest were uncertain. For those who were uncertain or unlikely to have the vaccine, efficacy and safety were the key issues. We asked witnesses what were the key risks to public confidence in the COVID-19 vaccines. NHSE&I that these were very similar to other vaccine programmes that the NHS ran successfully each year, but that the scale of the programme and the newness of the supply chain were different. The Department of Health & Social Care recognised the need for clear messaging to enable the Type: conclusion | Number: 29 | Response status: not_addressed Government response: Accept. The government has worked closely with NHS E/I, PHE, the MHRA and JCVI to communicate clearly to the public about the development and rollout of the authorised vaccines. Public information about the vaccine programme, the vaccines themselves, and relevant